These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23991987)

  • 1. Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
    Zhang X; Jin FS; Zhang LG; Chen RX; Zhao JH; Wang YN; Wang EF; Jiang ZD
    Asian Pac J Cancer Prev; 2013; 14(7):4261-5. PubMed ID: 23991987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
    Han QL; Zhou YH; Lyu Y; Yan H; Dai GH
    J Clin Pharm Ther; 2018 Apr; 43(2):163-169. PubMed ID: 29214667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
    Zhu Y; Qi M; Lao L; Wang W; Hua L; Bai G
    Genet Test Mol Biomarkers; 2014 May; 18(5):306-12. PubMed ID: 24625353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
    Xie H; Jiang W; Jiang J; Wang Y; Kim R; Liu X; Liu X
    Cancer; 2013 Jan; 119(1):173-81. PubMed ID: 22736490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
    Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
    Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
    Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
    Gong W; Zhang X; Wu J; Chen L; Li L; Sun J; Lv Y; Wei X; Du Y; Jin H; Dong J
    Lung Cancer; 2012 Mar; 75(3):374-80. PubMed ID: 21889227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
    Valsecchi ME; Holdbrook T; Leiby BE; Pequignot E; Littman SJ; Yeo CJ; Brody JR; Witkiewicz AK
    BMC Cancer; 2012 Mar; 12():104. PubMed ID: 22436573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
    Zhao LP; Xue C; Zhang JW; Hu ZH; Zhao YY; Zhang J; Huang Y; Zhao HY; Zhang L
    Chin J Cancer; 2012 Oct; 31(10):476-83. PubMed ID: 22692073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
    World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer.
    Lin X; Tan Y; Pan L; Tian Z; Lin L; Su M; Ou G; Chen Y
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):237-251. PubMed ID: 38040978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
    Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
    Akita H; Zheng Z; Takeda Y; Kim C; Kittaka N; Kobayashi S; Marubashi S; Takemasa I; Nagano H; Dono K; Nakamori S; Monden M; Mori M; Doki Y; Bepler G
    Oncogene; 2009 Aug; 28(32):2903-9. PubMed ID: 19543324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.